All News
#ACR18 poster 1265:
Gout management in primary care can be improved with a thoughtful structured approach. Quantity and quality of ULT improves; proportion failing to meet SUA target fell from 64% to 39%. Exemplary approach to gout care.
@RheumNow https://t.co/GeE5RRU0Pr
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)
Almost time for one of my perennial ACR favourites: Tech Tools for Rheumatology by @DrBhana
#ACR18 https://t.co/Loe9C16WlO
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)
Good to see a virtual appearance by @RonanTKavanagh here at #ACR18, via @DrBhana’s excellent presentation. https://t.co/fxqFnYO8jr
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)
.@BrennanSpiegel Digital sensors are now available for multiple organ systems #ACR18 @RheumNow https://t.co/RFMA9eArbt
Suleman Bhana, MD DrBhana ( View Tweet)
Numbers just released - 15,000 attendees at #ACR18 from 106 countries
Felicity Nelson frogsandstars ( View Tweet)
Well done to our outstanding former registrar Bess Leonardo for her excellent work that was presented at #ACR18 today (poster 2353), looking at how RA patients access information about MTX. https://t.co/PF0BNQpdKl
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)
2018 Great Debate examines questions about hydroxychloroquine dosing guidelines https://t.co/ltOnUmtrzw
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)
This enjoyable #ACR18 #fibromyalgia session is an appropriate time for a couple of periodic reminders:
1. Pain is an output of the brain (not an input)
2. Fibromyalgia is best conceptualised as a *description*, not an *explanation*
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)
#Vasculitis oral abstract session at #ACR18: back to back abstracts on use of #leflunomide for #GCA and #PMR. Promising results on efficacy and #steroid sparing effect. Could it become a standard alternative when tocilizumab contraindicated or not available?
Angelo Gaffo ALGaffoRheumMD ( View Tweet)
#ACR18 #2923: Persistence of bone marrow oedema within the same SIJ quadrant associated with structural damage at 5 years in patients with early axial SpA.
@RheumNow
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)
#ACR18 #2924 - Great work by the always-impressive Sofia Ramiro using DESIR data in early AxSpA. Early progression (2-5yrs) of syndesmophytes predicted by baseline inflammation (MRI) and damage (XR).
@RheumNow https://t.co/D9aGXFUtcd
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)
#ACR18 #2952 - Validation of a clinical risk score for NSAID toxicity. Most patients fall into intermediate category, but 5% low risk, 25% high risk: probably useful in clinic if externally validated & calculator were available at point of care.
@RheumNow https://t.co/DjdaYLwuX3
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)
#ACR18 #2954 Brave presentation from Dr Jin under pressure from a feisty Jim O’Dell in the audience. Analysis of US claims database regarding combo Rx for RA. Only 3% of MTX combo is triple therapy (cf MTX+TNFi). No evidence for change over time.
@RheumNow
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)
#ACR18 #2956 Interesting UK CPRD data on opioid prescribing presented by @MeghnaJani - UK prescribers seem to be getting the message about opioids, but work still to be done (esp regarding use of strong opioids, with are hard to transition off).
@RheumNow https://t.co/LwyVVVfw8i
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)
RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Novartis. All content chosen and distributed by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Patients with elevated IL-6 baseline levels had greater response to sarilumab compared with MTX or adalimumab. #L08 https://t.co/uxMOSD2B1E @RheumNow #ACR18
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Possible efficacy with LEF/HCQ in primary SS. #L10 https://t.co/1BKglr3JSF @RheumNow #ACR18
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Horizon Pharma. All content chosen and distributed by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
IXE efficacious in r-axSpA at Week 16 in TNF failure pts. #L12 https://t.co/MCpXDj9Z2o @RheumNow #ACR18
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
SEC shows efficacy in AS over 5 years. #L13 https://t.co/JQFdYlA3ku @RheumNow #ACR18
Links:
Dr. Rachel Tate uptoTate ( View Tweet)